Literature DB >> 6743422

Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy.

P T Wilmshurst, D S Thompson, S M Juul, B S Jenkins, D J Coltart, M M Webb-Peploe.   

Abstract

The effects of intravenous amrinone and sodium nitroprusside on haemodynamic indices, left ventricular contractility, and myocardial metabolism were compared in patients with cardiac failure. All patients received one dose of each drug and some received serial doses. Eight patients had dilated cardiomyopathy and six coronary artery disease, but the responses to the two drugs were independent of the aetiology of cardiac failure. Both drugs lowered left ventricular end diastolic pressure and aortocoronary sinus oxygen difference and increased cardiac index and left ventricular efficiency; these effects were dose related. Although the effects of the drugs on peripheral blood substrate concentrations were different, those on myocardial substrate metabolism were identical. Pressure derived indices of contractility in each group of patients were unaltered by either drug. After amrinone administration increases in cardiac index were related to plasma amrinone concentration, but alterations in contractility were not. In four individual patients increases in contractility were associated with alterations in plasma metabolite concentrations, which suggested that catecholamine release had occurred. For the groups of patients as a whole, however, amrinone had effects which did not differ significantly from those of the pure vasodilator, nitroprusside. There was no evidence that amrinone had a direct positive inotropic effect since no dose related changes in indices of contractile function could be established.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743422      PMCID: PMC481582          DOI: 10.1136/hrt.52.1.38

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  38 in total

1.  Positive inotropic effects of dibutyryl cyclic adenosine 3',5'-monophosphate.

Authors:  C L Skelton; G S Levey; S E Epstein
Journal:  Circ Res       Date:  1970-01       Impact factor: 17.367

2.  Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function.

Authors:  A Timmis; K Daly; D E Jewitt
Journal:  Br Heart J       Date:  1983-07

3.  [Effect of dibutyryl cyclic AMP on hemodynamics and metabolism of carbohydrates and lipid after extracorporeal circulation in cardiac surgical patients (author's transl)].

Authors:  K Satoh
Journal:  Nihon Kyobu Geka Gakkai Zasshi       Date:  1980-03

4.  High-performance liquid chromatographic analysis of amrinone and its N-acetyl derivative in plasma. Pharmacokinetics of amrinone in the dog.

Authors:  M P Kullberg; B Dorrbecker; J Lennon; E Rowe; J Edelson
Journal:  J Chromatogr       Date:  1980-01-04

5.  Clinical experience with amrinone in patients with advanced congestive heart failure.

Authors:  E L Kinney; B Carlin; J O Ballard; J M Burks; W F Hallahan; R Zelis
Journal:  J Clin Pharmacol       Date:  1982-10       Impact factor: 3.126

6.  [Hemodynamic effects of various doses of a new inotropic: amrinoma].

Authors:  M Cárdenas; A Vidaurri
Journal:  Arch Inst Cardiol Mex       Date:  1979 Sep-Oct

7.  Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.

Authors:  M Endoh; S Yamashita; N Taira
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

8.  Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.

Authors:  D S Baim; A V McDowell; J Cherniles; E S Monrad; J A Parker; J Edelson; E Braunwald; W Grossman
Journal:  N Engl J Med       Date:  1983-09-29       Impact factor: 91.245

9.  Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy.

Authors:  C V Leier; K Dalpiaz; P Huss; J B Hermiller; R D Magorien; T M Bashore; D V Unverferth
Journal:  Am J Cardiol       Date:  1983-08       Impact factor: 2.778

10.  Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate.

Authors:  J Bayliss; M Norell; R Canepa-Anson; S R Reuben; P A Poole-Wilson; G C Sutton
Journal:  Br Heart J       Date:  1983-03
View more
  14 in total

1.  Noninvasive assessment of the inodilator action of amrinone in healthy man.

Authors:  C de Mey; D Enterling; G Hanft
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Haemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogs.

Authors:  A Dorszewski; B Müller-Beckmann; L Kling; G Sponer
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

3.  Effects of commonly used inotropes on myocardial function and oxygen consumption under constant ventricular loading conditions.

Authors:  Elizabeth S DeWitt; Katherine J Black; Ravi R Thiagarajan; James A DiNardo; Steven D Colan; Francis X McGowan; John N Kheir
Journal:  J Appl Physiol (1985)       Date:  2016-05-05

4.  The positive inotropic response to milrinone in isolated human and guinea pig myocardium.

Authors:  L Brown; M Näbauer; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-10       Impact factor: 3.000

Review 5.  Cardiovascular effects of forskolin and phosphodiesterase-III inhibitors.

Authors:  M Schlepper; J Thormann; V Mitrovic
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

6.  Effects of amrinone on cardiac contraction and relaxation in isolated, perfused rat heart.

Authors:  Y X Ma; H Y Zhao
Journal:  J Tongji Med Univ       Date:  1994

Review 7.  Inotropic support of the critically ill patient. A review of the agents.

Authors:  P J Kulka; M Tryba
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

8.  Intravenous fenoldopam infusion in severe heart failure.

Authors:  J J Patel; A S Mitha; P Sareli; J B de Vaal
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

Review 9.  Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.

Authors:  T A Fischer; R Erbel; N Treese
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

Review 10.  Intravenous vasodilator therapy in congestive heart failure.

Authors:  Kourosh Moazemi; Jatinder S Chana; Anna Marie Willard; Abraham G Kocheril
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.